Summary of Cidara Therapeutics (CDTX) Core Viewpoint - Cidara Therapeutics (CDTX) shows potential for significant upside, with a mean price target of $38 indicating a 64.5% increase from the current price of $23.10 [1]. Price Target Analysis - The average price target consists of six estimates ranging from $33 to $46, with a standard deviation of $5.87, suggesting a consensus among analysts [2]. - The lowest estimate indicates a 42.9% increase, while the highest suggests a 99.1% upside [2]. - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [7]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [9]. - The Zacks Consensus Estimate for the current year has risen by 50.5% over the past month, with no negative revisions [10]. - CDTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, and reliance solely on them may not yield favorable returns [5][8]. - Analysts may set optimistic price targets due to business incentives, which can inflate expectations [6].

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the "Other pharmaceuticals as preventive tools" panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled "What research is important to prepare and respond to H5N1 influenza outbreaks," will be held virtuall ...

SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara’s presentations will highlight the study design, demographic information, and preliminary safety data from the ongoi ...

SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara's presentations will highlight the study design, demographic information, and preliminary safety data from the ongoin ...

Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced the publication of preclinical data assessing CD388, the company's influenza DFC, in the peer-reviewed scientific journal Nature Microbiology. The article, entitled "Dru ...

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results SAN DIEGO, March 6, 2025 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. ® "2024 was a transformational year for Cidara as we rea ...

Core Insights - Cidara Therapeutics reported a transformational year in 2024, highlighted by the reacquisition of rights to the CD388 program and raising a total of $345 million to support its clinical trials [2][6] - The company completed enrollment for the Phase 2b NAVIGATE trial, which evaluates CD388 for the prevention of seasonal influenza, with results expected in mid-2025 [6][9] - Cidara's financial results showed a significant increase in cash reserves, with cash and equivalents totaling $196.2 million as of December 31, 2024, compared to $35.8 million in 2023 [6][15] Recent Corporate Highlights - Cidara completed the enrollment of 5,000 subjects in the Phase 2b NAVIGATE trial across the U.S. and UK [6] - The company raised $105 million in a private placement led by Venrock Healthcare Capital Partners [6] - Equity research coverage was significantly expanded with new ratings from Guggenheim, Cantor, and RBC [6] Financial Results - Collaboration revenue was reported as zero for Q4 2024, down from $2.8 million in Q4 2023, and $1.3 million for the full year 2024, down from $23.3 million in 2023 [12][9] - Research and development expenses increased to $46.9 million for Q4 2024 and $71.9 million for the full year, compared to $8.0 million and $36.8 million in 2023, primarily due to the CD388 trial [9][12] - The net loss for Q4 2024 was $52.3 million, compared to $3.2 million in Q4 2023, and the full year net loss was $169.8 million, compared to $22.9 million in 2023 [12][9] Balance Sheet Data - As of December 31, 2024, total assets were $214.8 million, significantly up from $67.0 million in 2023 [15] - Total liabilities decreased to $51.5 million from $75.2 million in 2023, while total stockholders' equity improved to $163.3 million from a deficit of $8.2 million [15]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-1537286 (State or Other Jurisdicti ...

Company Overview - Cidara Therapeutics, Inc. is a biotechnology company focused on developing drug-Fc conjugate (DFC) immunotherapies using its proprietary Cloudbreak® platform [1][3] - The company's lead DFC candidate, CD388, is designed for long-acting antiviral treatment aimed at universal prevention of seasonal and pandemic influenza with a single dose [3] Leadership Change - Frank Karbe has been appointed as the Chief Financial Officer (CFO) effective February 24, 2025, succeeding Preetam Shah, who will transition to a consulting role [1][2] - Karbe brings over 25 years of leadership experience in life sciences and healthcare, having previously served as CEO of Better Therapeutics and CFO of Myovant Sciences, where he played a key role in raising over $2 billion in capital [2] Clinical Development - Cidara is advancing its long-acting influenza antiviral drug CD388 through the Phase 2b NAVIGATE study, with plans for Phase 3 and beyond [2] - CD388 received Fast Track Designation from the FDA in June 2023, and a Phase 2b trial was initiated in September 2024 [3] Equity Awards - In connection with Karbe's appointment, Cidara's Compensation Committee granted him stock options and restricted stock units (RSUs) for a total of 172,500 shares, with a vesting schedule over four years [4][5] - The stock options will have an exercise price equal to the closing price of Cidara's common stock on the grant date [4] Inducement Incentive Plan - The equity awards were granted as an inducement for Karbe's employment, in accordance with Nasdaq Listing Rule 5635(c)(4) [5][6]

Core Viewpoint - Cidara Therapeutics is actively participating in the Guggenheim Securities SMID Cap Biotech Conference, showcasing its innovative drug-Fc conjugate (DFC) immunotherapies aimed at improving patient care for serious diseases [1][2]. Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop novel DFCs, which consist of targeted small molecules or peptides linked to a human antibody fragment [3]. - The lead DFC candidate, CD388, is designed for long-acting antiviral treatment to provide universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3]. - CD388 received Fast Track Designation from the U.S. FDA in June 2023, and the company completed Phase 2b enrollment in December 2024 [3]. - Cidara has also developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024 [3]. Event Participation - Jeffrey Stein, Ph.D., President and CEO of Cidara, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, at 1:30 PM ET [1]. - Cidara will engage in one-on-one investor meetings during the conference, with interested investors encouraged to contact their Guggenheim representative [2].